DNA Repair Gene XRCC1 Polymorphisms, Smoking, and Bladder Cancer Risk: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Li, Shan ^a   Peng, Qiliu ^a   Chen, Yongbin ^a   You, Jianpeng ^b   Chen, Zhiping ^b   Deng, Yan ^a   Lao, Xianjun ^a   Wu, Huiling ^a   Qin, Xue ^a   Zeng, Zhiyu ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

XRCC1 PROTEIN; DNA BINDING PROTEIN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ARTICLE; BLADDER CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA REPAIR; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SMOKING; XRCC1 GENE; ASIAN; BLADDER TUMOR; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; RISK;

ASIAN CONTINENTAL ANCESTRY GROUP; DNA-BINDING PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; POLYMORPHISM, GENETIC; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 84883644129     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073448     Document Type: Article

References (57)

1. Verma S, Rajesh A, Prasad SR, Gaitonde K, Lall CG, et al. (2012) Urinary bladder cancer: role of MR imaging. RadioGraphics 32: 371-387. doi:10.1148/rg.322115125. PubMed: 22411938.
2. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, et al. (2004) Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 25: 729-734. PubMed: 14688016.
3. Cohen SM, Shirai T, Steineck G, (2000) Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl: pp. 105-115. PubMed: 11144890.
4. Hoeijmakers JH, (2001) Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374. doi:10.1038/35077232. PubMed: 11357144.
5. Wood RD, Mitchell M, Sgouros J, Lindahl T, (2001) Human DNA repair genes. Science 291: 1284-1289. doi:10.1126/science.1056154. PubMed: 11181991.
6. Huang M, Dinney CP, Lin X, Lin J, Grossman HB, et al. (2007) High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev 16: 84-91. doi:10.1158/1055-9965.EPI-06-0712. PubMed: 17220334.
7. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, et al. (1998) XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18: 3563-3571. PubMed: 9584196.
8. Vidal AE, Boiteux S, Hickson ID, Radicella JP (2001) XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J 20: 6530-6539.
9. Caldecott KW, Aoufouchi S, Johnson P, Shall S, (1996) XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro. Nucleic Acids Res 24: 4387-4394. doi:10.1093/nar/24.22.4387. PubMed: 8948628.
10. Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA, (2001) DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 10: 125-131. PubMed: 11219769.
11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012.
12. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, et al. (2005) Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 162: 201-211. doi:10.1093/aje/kwi184. PubMed: 15987731.
13. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. doi:10.1016/0197-2456(86)90046-2. PubMed: 3802833.
14. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748. PubMed: 13655060.
15. Galbraith RF, (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7: 889-894. doi:10.1002/sim.4780070807. PubMed: 3413368.
16. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. doi:10.1136/bmj.315.7109.629. PubMed: 9310563.
17. Mittal RD, Singh R, Manchanda PK, Ahirwar D, Gangwar R, et al. (2008) XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Cancer Biol Ther 7: 645-650. doi:10.4161/cbt.7.5.5763. PubMed: 18364571.
18. Stern MC, Umbach DM, Lunn RM, Taylor JA, (2002) DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 11: 939-943. PubMed: 12223443.
19. Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC, et al. (2006) Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis 27: 1030-1037. doi:10.1093/carcin/bgi284. PubMed: 16311243.
20. Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, et al. (2001) DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 92: 562-567. doi:10.1002/ijc.1228. PubMed: 11304692.
21. Ricceri F, Guarrera S, Sacerdote C, Polidoro S, Allione A, et al. (2010) ERCC1 haplotypes modify bladder cancer risk: a case-control study. DNA Repair (Amst) 9: 191-200. doi:10.1016/j.dnarep.2009.12.002. PubMed: 20061190.
22. Manuguerra M, Matullo G, Veglia F, Autrup H, Dunning AM, et al. (2007) Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. Carcinogenesis 28: 414-422. PubMed: 16956909.
23. Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, et al. (2006) Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 95: 561-570. doi:10.1038/sj.bjc.6603290. PubMed: 16880786.
24. Sakano S, Matsumoto H, Yamamoto Y, Kawai Y, Eguchi S, et al. (2006) Association between DNA repair gene polymorphisms and p53 alterations in Japanese patients with muscle-invasive bladder cancer. Pathobiology 73: 295-303. doi:10.1159/000099124. PubMed: 17374967.
25. Stern MC, Conway K, Li Y, Mistry K, Taylor JA, (2006) DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Mol Carcinog 45: 715-719. doi:10.1002/mc.20210. PubMed: 16652373.
26. Ryk C, Kumar R, Sanyal S, de Verdier PJ, Hemminki K, et al. (2006) Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett 241: 142-149. doi:10.1016/j.canlet.2005.10.025. PubMed: 16343742.
27. Sanyal S, De Verdier PJ, Steineck G, Larsson P, Onelöv E, et al. (2007) Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms. Acta Oncol 46: 31-41. doi:10.1080/02841860600812693. PubMed: 17438703.
28. Lao T, Gu W, Huang Q, (2008) A meta-analysis on XRCC1 R399Q and R194W polymorphisms, smoking and bladder cancer risk. Mutagenesis 23: 523-532. doi:10.1093/mutage/gen046. PubMed: 18765423.
29. Wang C, Sun Y, Han R, (2008) XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis. Urology 72: 869-872. doi:10.1016/j.urology.2007.12.059. PubMed: 18336890.
30. Goode EL, Ulrich CM, Potter JD, (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11: 1513-1530. PubMed: 12496039.
31. Shen M, Hung RJ, Brennan P, Malaveille C, Donato F, et al. (2003) Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy. Cancer Epidemiol Biomarkers Prev 12: 1234-1240. PubMed: 14652287.
32. Kelsey KT, Park S, Nelson HH, Karagas MR, (2004) A population-based case-control study of the XRCC1 Arg399Gln polymorphism and susceptibility to bladder cancer. Cancer Epidemiol Biomarkers Prev 13: 1337-1341. PubMed: 15298955.
33. Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, et al. (2005) Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. Cancer Epidemiol Biomarkers Prev 14: 2569-2578. doi:10.1158/1055-9965.EPI-05-0189. PubMed: 16284380.
34. Broberg K, Björk J, Paulsson K, Höglund M, Albin M, (2005) Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 26: 1263-1271. PubMed: 15746160.
35. Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, et al. (2006) DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 27: 997-1007. doi:10.1093/carcin/bgi280. PubMed: 16308313.
36. Karahalil B, Kocabas NA, Ozçelik T, (2006) DNA repair gene polymorphisms and bladder cancer susceptibility in a Turkish population. Anticancer Res 26: 4955-4958. PubMed: 17214369.
37. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, et al. (2006) Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 78: 464-479. doi:10.1086/500848. PubMed: 16465622.
38. Figueroa JD, Malats N, Real FX, Silverman D, Kogevinas M, et al. (2007) Genetic variation in the base excision repair pathway and bladder cancer risk. Hum Genet 121: 233-242. doi:10.1007/s00439-006-0294-y. PubMed: 17203305.
39. Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE, (2007) DNA repair gene XRCC1 polymorphisms and bladder cancer risk. BMC Genet 8: 13. doi:10.1186/1471-2156-8-13. PubMed: 17425776.
40. Fontana L, Bosviel R, Delort L, Guy L, Chalabi N, et al. (2008) DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort. Anticancer Res 28: 1853-1856. PubMed: 18630471.
41. Wang M, Qin C, Zhu J, Yuan L, Fu G, et al. (2010) Genetic variants of XRCC1, APE1, and ADPRT genes and risk of bladder cancer. DNA Cell Biol 29: 303-311. doi:10.1089/dna.2009.0969. PubMed: 20218899.
42. Arizono K, Osada Y, Kuroda Y, (2008) DNA repair gene hOGG1 codon 326 and XRCC1 codon 399 polymorphisms and bladder cancer risk in a Japanese population. Jpn J Clin Oncol 38: 186-191. doi:10.1093/jjco/hym176. PubMed: 18272472.
43. Narter KF, Ergen A, Agaçhan B, Görmüs U, Timirci O, et al. (2009) Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). Anticancer Res 29: 1389-1393. PubMed: 19414392.
44. Zhi Y, Yu J, Liu Y, Wei Q, Yuan F, et al. (2012) Interaction between polymorphisms of DNA repair genes significantly modulated bladder cancer risk. Int J Med Sci 9: 498-505. doi:10.7150/ijms.4799. PubMed: 22927776.
45. Andrew AS, Karagas MR, Nelson HH, Guarrera S, Polidoro S, et al. (2008) DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy. Hum Hered 65: 105-118. doi:10.1159/000108942. PubMed: 17898541.
46. Wen H, Ding Q, Fang ZJ, Xia GW, Fang J, (2009) Population study of genetic polymorphisms and superficial bladder cancer risk in Han-Chinese smokers in Shanghai. Int Urol Nephrol 41: 855-864. doi:10.1007/s11255-009-9560-y. PubMed: 19350405.
47. Covolo L, Placidi D, Gelatti U, Carta A, Scotto Di Carlo A, et al. (2008) Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case-control study. Eur J Epidemiol 23: 355-362. doi:10.1007/s10654-008-9238-2. PubMed: 18365755.
48. Gao W, Romkes M, Zhong S, Nukui T, Persad RA, et al. (2010) Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol Rep 24: 257-262. PubMed: 20514470.
49. Mittal RD, Mandal RK, Gangwar R, (2012) Base excision repair pathway genes polymorphism in prostate and bladder cancer risk in North Indian population. Mech Ageing Dev 133: 127-132. doi:10.1016/j.mad.2011.10.002. PubMed: 22019847.
50. Wu W, (2005) Study on the relationship between polymorphisms of JWA and XRCC1 genes and susceptipility to bladder cancer (article in chinese). Available: http://d.g.wanfangdata.com.cn/ Thesis_Y917543.aspx. Accessed 20 Feb 2013.
51. Zhang W, Xiang YB, Cheng JR, Shao CX, Fang RR, et al. (2006) A Case-control Study of Polymorphism of XRCC1 Gene the Risk of Bladder Cancer. Zhong Guo Zhong Liu 15: 667-672. Available: http://d.g.wanfangdata.com.cn/Periodical_zgzl 200610007.aspx. Accessed 20 Feb 2013).
52. Wen H, Feng CC, Fang ZJ, Xia GW, Jiang HW, et al. (2012) Study on Bladder Cancer Susceptibility and Genetic Polymorphisms of XPC, XPG, and CYP in Smokers and Non-Smokers. Actas Urol Esp, 37: 259-265. PubMed: 23246108.
53. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC, (2011) Association between smoking and risk of bladder cancer among men and women. JAMA 306: 737-745. doi:10.1001/jama.2011.1142. PubMed: 21846855.
54. Morrison AS, Buring JE, Verhoek WG, Aoki K, Leck I, et al. (1984) An international study of smoking and bladder cancer. J Urol 131: 650-654. PubMed: 6708176.
55. Benhamou S, Sarasin A, (2005) ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 161: 1-14. doi:10.1093/aje/kwi018. PubMed: 15615908.
56. Friedberg EC, (2003) DNA damage and repair. Nature 421: 436-440. doi:10.1038/nature01408. PubMed: 12540918.
57. Ioannidis JP, Patsopoulos NA, Evangelou E, (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335: 914-916. doi:10.1136/bmj.39343.408449.80. PubMed: 17974687.